Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SKB264 + Pembrolizumab in First-Line PD-L1+ Advanced NSCLC
NCT06448312Phase 3Active, not recruiting
- Sponsor
- Kelun-Biotech
- Start
- Jun 2024
- Primary completion
- Nov 2026
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of sacituzumab tirumotecan in non-small cell lung cancer (NSCLC), sponsored by Kelun-Biotech. Started Jun 2024; status: active, not recruiting.
02
Drugs
sacituzumab tirumotecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06448312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448312.